Werner Stilmant Named General Manager of ProductLife Group Belgium and Germany
Life sciences outsourcing and consulting services specialist ProductLife Group (PLG) has announced another strategic senior management appointment as part of its continued international growth plans. Werner Stilmant has joined the group as General Manager of ProductLife Group Belgium and Germany.
Werner brings broad experience to the role, from his years in clinical research, business process management, outsourcing and consulting. He started out in the life sciences industry as a clinical researcher before moving into the distribution and supply chain side of the business. In each of his managerial roles to date, Werner has applied his knowledge of lean concepts to improving and streamlining business processes.
His experience in leading both small and large groups gives him the flexibility and people management skills needed to manage PLG’s diverse and highly skilled teams in Belgium and Germany, according to Adam Sherlock, the group’s CEO. Werner will draw on his experiences within pharma, contract research organisations (CROs), and as a consultant to help his team optimise their talent pools.
“Werner’s diplomatic and open communication style is well suited to the PLG culture and will serve to underscore our company’s commitment to building new business opportunities, enhancing our market footprint, and further integrating our core regulatory, pharmacovigilance, and quality capabilities. He is a very welcome addition to the senior team,” Adam said.
The appointment of a new general manager for Belgium and Germany is the latest in a series of high-profile leadership changes at PLG — designed to reinforce the top team as the group advances its plans to expand deeper into Europe and to penetrate new markets. Other recent changes have included a separation of the roles of Chairman and CEO.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.